Leukemia AML – Favorable
Reviewed by Oncology Team, HealOnco | Last updated: 2026-04
What AML – Favorable Means
Acute promyelocytic (t(15;17)), NPM1+ without FLT3-ITD; core binding leukemias (t(8;21), inv16)
Treatment Approach for AML – Favorable
7+3 induction ± high-dose cytarabine; ATRA + arsenic for APL; selective HSCT for consolidation
Survival Rates and Prognosis
The 5-year survival rate for leukemia at AML – Favorable is approximately 70-80% 5-year overall survival. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| ALL – Low Risk | 80-90% 5-year event-free survival | Standard induction + consolidation + maintenance (2.5-3 years); CNS prophylaxis… |
| ALL – High Risk | 40-60% 5-year event-free survival | Intensified chemotherapy + TKI (if BCR-ABL+) + consideration of allogeneic HSCT |
| AML – Intermediate | 40-60% 5-year overall survival | 7+3 or lower-intensity induction based on age/fitness; standard post-remission… |
| AML – Unfavorable | 5-20% 5-year overall survival | Consider lower-intensity chemotherapy, hypomethylating agents (azacitidine), or… |
| CML – Chronic Phase | >20 years with TKI monotherapy | First-line TKI (imatinib 400mg, dasatinib 100mg, or nilotinib 300mg daily);… |
| CML – Accelerated Phase | 2-3 years median | Second or third-line TKI; early HSCT consideration; close MRD monitoring |
| CML – Blast Crisis | 3-6 months without HSCT | Induction chemotherapy + TKI + urgent HSCT; ponatinib for T315I mutations |
| CLL – Rai Stage 0 | 8-10 years median | Watch-and-wait; defer therapy until symptomatic progression |
| CLL – Rai Stage III-IV | 2-5 years without therapy | Chemoimmunotherapy (rituximab + fludarabine) or venetoclax-based regimens;… |
Leukemia Treatment in Top Cities
Diagnosed with AML – Favorable Leukemia?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free Consultation